Boston Scientific (BSX) PT Raised to $120 at Jefferies

Jefferies analyst Matthew Taylor raised the price target on Boston Scientific (NYSE: BSX) to $120.00 (from $100.00) while maintaining a Buy rating.

The analyst comments "BSX reported 4Q24 sales of $4.56B, +19.5% organic, vs cons $4.42B and EPS of $0.70 +27% vs cons $0.66. BSX introduced '25 guidance of +10-12% organic growth vs cons 9.4% and EPS of $2.80-$2.87 +13% vs cons $2.79. This was a standout quarter, driven by upside in EP/PFA, with good results in WATCHMAN/across the board. We model the high end of guidance in '25, viewing the range as conservative, and are raising our #s and PT; reiterate Buy."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Boeing lands two U.S. defense contracts worth over $711M